About
Celcuity is a clinical-stage, publicly traded biotechnology company headquartered in Minneapolis that focuses on extending the lives of cancer patients through targeted therapies for solid tumors. Its flagship product, gedatolisib, is an intravenously administered, first-in-class PI3K/AKT/mTOR pathway inhibitor with a unique mechanism of action and differentiated pharmacokinetics compared to existing PI3K or mTOR therapies. The company is advancing gedatolisib in Phase 3 trials for hormone-receptor positive/HER2-negative advanced breast cancer in both first- and second-line settings, while also evaluating a combination with darolutamide in metastatic castration-resistant prostate cancer. Celcuity's distinctive approach lies in its comprehensive targeting of cellular drivers of tumor growth, positioning it at the forefront of innovative, multi-pathway cancer therapeutics.
